Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Dennis Verzijl"'
Autor:
Ida H. Hiemstra, Kim C.M. Santegoets, Maarten L. Janmaat, Bart E.C.G. De Goeij, Wessel Ten Hagen, Sanne van Dooremalen, Peter Boross, Jeroen van den Brakel, Sieto Bosgra, Grietje Andringa, Berris van Kessel-Welmers, Dennis Verzijl, Richard G. Hibbert, Kristine A. Frerichs, Tuna Mutis, Niels W.C.J. van de Donk, Tahamtan Ahmadi, David Satijn, A. Kate Sasser, Esther C.W. Breij
Publikováno v:
EBioMedicine, Vol 93, Iss , Pp 104663- (2023)
Summary: Background: HexaBody®-CD38 (GEN3014) is a hexamerization-enhanced human IgG1 that binds CD38 with high affinity. The E430G mutation in its Fc domain facilitates the natural process of antibody hexamer formation upon binding to the cell surf
Externí odkaz:
https://doaj.org/article/f33bd39a5fdd41bc885381f56bdbe832
Autor:
Alexander Muik, Isil Altintas, Friederike Gieseke, Kristina B Schoedel, Saskia M Burm, Aras Toker, Theodora W. Salcedo, Dennis Verzijl, David Eisel, Christian Grunwitz, Lena M Kranz, Mathias Vormehr, David P.E. Satijn, Mustafa Diken, Sebastian Kreiter, Kate Sasser, Tahamtan Ahmadi, Özlem Türeci, Esther C.W. Breij, Maria Jure-Kunkel, Ugur Sahin
Publikováno v:
OncoImmunology, Vol 11, Iss 1 (2022)
Immune checkpoint inhibitors (ICI) targeting the PD-1/PD-L1 axis have changed the treatment paradigm for advanced solid tumors; however, many patients experience treatment resistance. In preclinical models 4-1BB co-stimulation synergizes with ICI by
Externí odkaz:
https://doaj.org/article/c2df5e33bb4545efb02c509f371c1d5a
Autor:
Maria Jure-Kunkel, Homer C Adams III, Kate Sasser, Mark Fereshteh, Alexander Muik, Isil Altintas, Friederike Gieseke, Aras Toker, Özlem Türeci, Tahamtan Ahmadi, Ugur Sahin, Dennis Verzijl, Kristina B Schoedel, Jordan M Blum, Bianca Sänger, Saskia M Burm, Eliana Stanganello, Vanessa M Spires, Fulvia Vascotto, Juliane Quinkhardt, Mustafa Diken, David P E Satijn, Sebastian Kreiter, Esther C W Breij
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 6 (2022)
Externí odkaz:
https://doaj.org/article/026b8577fc804412a127d45c0c573c04
Autor:
Kate Sasser, Esther Breij, Mischa Houtkamp, Stefanie De Poot, Louise Koopman, Laura Smits-de Vries, Frederikke Lihme Egerod, Sebastiaan Wubben, Madelon Paauwe, Edward van den Brink, Andrea Gorlani, Dennis Verzijl
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/d407118526334d7e82d8f9c77b1ec4b4
Autor:
Ignacio Melero, Maria Jure-Kunkel, Uğur Şahin, Tahamtan Ahmadi, Ulf Forssmann, Özlem Türeci, Kate Sasser, Eleni Lagkadinou, Gaurav Bajaj, Esther C.W. Breij, Sebastian Kreiter, David Satijn, Mustafa Diken, Mark Fereshteh, Edward N. van den Brink, Aras Toker, Theo S. Plantinga, Juliane Quinkhardt, Angelica Sette, Fulvia Vascotto, Dennis Verzijl, Eliana Stanganello, Saskia M. Burm, Theodora W. Salcedo, Bianca Sänger, Jordan M. Blum, Kristina B. Schoedel, Maria E. Rodriguez-Ruiz, Guzman Alonso, Patricia M. LoRusso, Emiliano Calvo, Corinne Maurice-Dror, Eytan Ben-Ami, Ravit Geva, Friederike Gieseke, Isil Altintas, Elena Garralda, Alexander Muik
Checkpoint inhibitors (CPI) have revolutionized the treatment paradigm for advanced solid tumors; however, there remains an opportunity to improve response rates and outcomes. In preclinical models, 4-1BB costimulation synergizes with CPIs targeting
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77571654a67b8230111048825587e8ec
https://doi.org/10.1158/2159-8290.c.6549569
https://doi.org/10.1158/2159-8290.c.6549569
Autor:
Ignacio Melero, Maria Jure-Kunkel, Uğur Şahin, Tahamtan Ahmadi, Ulf Forssmann, Özlem Türeci, Kate Sasser, Eleni Lagkadinou, Gaurav Bajaj, Esther C.W. Breij, Sebastian Kreiter, David Satijn, Mustafa Diken, Mark Fereshteh, Edward N. van den Brink, Aras Toker, Theo S. Plantinga, Juliane Quinkhardt, Angelica Sette, Fulvia Vascotto, Dennis Verzijl, Eliana Stanganello, Saskia M. Burm, Theodora W. Salcedo, Bianca Sänger, Jordan M. Blum, Kristina B. Schoedel, Maria E. Rodriguez-Ruiz, Guzman Alonso, Patricia M. LoRusso, Emiliano Calvo, Corinne Maurice-Dror, Eytan Ben-Ami, Ravit Geva, Friederike Gieseke, Isil Altintas, Elena Garralda, Alexander Muik
Supplementary Figure from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e568b16421048c1e79b8dfceca7e687
https://doi.org/10.1158/2159-8290.22541198.v1
https://doi.org/10.1158/2159-8290.22541198.v1
Publikováno v:
Analytical Chemistry, 94(17), 6548-6556. American Chemical Society
Early diagnosis of cancer is essential for the efficacy of treatment. Our group recently developed RAPPID, a bioluminescent immunoassay platform capable of measuring a wide panel of biomarkers directly in solution. Here, we developed and systematical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aefa14c5a0af31f0abe8cb14c7facfa7
https://research.tue.nl/nl/publications/4a59c090-ecea-4d01-bf29-0edc36cdd474
https://research.tue.nl/nl/publications/4a59c090-ecea-4d01-bf29-0edc36cdd474
Autor:
Alexander Muik, Homer C Adams, Friederike Gieseke, Isil Altintas, Kristina B Schoedel, Jordan M Blum, Bianca Sänger, Saskia M Burm, Eliana Stanganello, Dennis Verzijl, Vanessa M Spires, Fulvia Vascotto, Aras Toker, Juliane Quinkhardt, Mark Fereshteh, Mustafa Diken, David P E Satijn, Sebastian Kreiter, Tahamtan Ahmadi, Esther C W Breij, Özlem Türeci, Kate Sasser, Ugur Sahin, Maria Jure-Kunkel
Publikováno v:
Journal for immunotherapy of cancer. 10(6)
BackgroundDespite the preclinical promise of CD40 and 4-1BB as immuno-oncology targets, clinical efforts evaluating CD40 and 4-1BB agonists as monotherapy have found limited success. DuoBody-CD40×4-1BB (GEN1042/BNT312) is a novel investigational Fc-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8ca1ed02245165ab397e37b5a3699c0
https://pubmed.ncbi.nlm.nih.gov/36096537
https://pubmed.ncbi.nlm.nih.gov/36096537
Autor:
Alexander Muik, Elena Garralda, Isil Altintas, Friederike Gieseke, Ravit Geva, Eytan Ben-Ami, Corinne Maurice-Dror, Emiliano Calvo, Patricia M. LoRusso, Guzman Alonso, Maria E. Rodriguez-Ruiz, Kristina B. Schoedel, Jordan M. Blum, Bianca Sänger, Theodora W. Salcedo, Saskia M. Burm, Eliana Stanganello, Dennis Verzijl, Fulvia Vascotto, Angelica Sette, Juliane Quinkhardt, Theo S. Plantinga, Aras Toker, Edward N. van den Brink, Mark Fereshteh, Mustafa Diken, David Satijn, Sebastian Kreiter, Esther C.W. Breij, Gaurav Bajaj, Eleni Lagkadinou, Kate Sasser, Özlem Türeci, Ulf Forssmann, Tahamtan Ahmadi, Uğur Şahin, Maria Jure-Kunkel, Ignacio Melero
Publikováno v:
Scientia
Checkpoint inhibitors (CPI) have revolutionized the treatment paradigm for advanced solid tumors; however, there remains an opportunity to improve response rates and outcomes. In preclinical models, 4-1BB costimulation synergizes with CPIs targeting
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f076437eb0766ba05d68e27c29cadd1
https://pubmed.ncbi.nlm.nih.gov/35491648
https://pubmed.ncbi.nlm.nih.gov/35491648
Autor:
Edward Van Den Brink, Dennis Verzijl, Frederikke Lihme Egerod, Sebastiaan Wubben, Mischa Houtkamp, Louise A. Koopman, Stefanie De Poot, Laura Smits-de Vries, Madelon Paauwe, Andrea Gorlani, Kate Sasser, Esther C.W. Breij
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundThe immune checkpoint protein B7H4 is expressed on malignant cells in various solid cancers, whereas its expression is highly restricted in normal tissue. B7H4 is therefore an attractive target for a CD3 bispecific antibody (bsAb) therapeut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4274189bcef70cf6960a85dd06613a02
https://doi.org/10.1136/jitc-2021-sitc2021.863
https://doi.org/10.1136/jitc-2021-sitc2021.863